SIGNAL TRANSDUCTION INHIBITORS AS NOVEL ANTICANCER DRUGS - WHERE ARE WE

被引:11
|
作者
WORKMAN, P
机构
[1] Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Scotland
关键词
D O I
10.1093/oxfordjournals.annonc.a058253
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:527 / 531
页数:5
相关论文
共 50 条
  • [1] Anticancer drugs: where are we now?
    De Simone, Giuseppina
    Supuran, Claudiu T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (07) : 525 - 527
  • [2] SIGNAL TRANSDUCTION INHIBITORS AND PIPELINE DRUGS
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Signal Transduction Inhibitors as Promising Anticancer Agents
    Kumar, Raj
    Dos Santos, Cedric
    Ahluwalia, Tarunveer Singh
    Singh, Sandeep
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [4] Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
    Mariaule, Gaele
    Belmont, Philippe
    MOLECULES, 2014, 19 (09) : 14366 - 14382
  • [5] Inhibitors of platelet signal transduction as anti-aggregatory drugs
    Geiger, J
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (05) : 865 - 890
  • [6] Protein kinase C inhibitors as novel anticancer drugs
    Goekjian, PG
    Jirousek, MR
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (12) : 2117 - 2140
  • [7] Novel chemical genetic approaches to the discovery of signal transduction inhibitors
    Shokat, K
    Velleca, M
    DRUG DISCOVERY TODAY, 2002, 7 (16) : 872 - 879
  • [8] SIGNAL-TRANSDUCTION BY RAS-LIKE GTPASES - A POTENTIAL TARGET FOR ANTICANCER DRUGS
    SPAARGAREN, M
    BISCHOFF, JR
    MCCORMICK, F
    GENE EXPRESSION, 1995, 4 (06): : 345 - 356
  • [9] Inhibitors of the Wnt/β-Catenin Signaling Pathway as Novel Anticancer Drugs
    Takahashi-Yanaga, Fumi
    Sasaguri, Toshiyuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 (02) : 179 - 183
  • [10] Inhibitors of cytokine signal transduction
    Wormald, S
    Hilton, DJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (02) : 821 - 824